NEW YORK (GenomeWeb News) — Venture capital group Summit Partners plans to make “a significant minority investment” in genomics and proteomics technology provider Fermentas International, the company said today.
Fermentas did not disclose the amount of the investment -- it said it “signed a definitive agreement to accept” Summit’s offer -- but said it plans to use the funds for organic growth and for new partnerships and acquisitions.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.